As as part of its overall Value Assessment Initiative, the Foundation has funded four Centers of Excellence in Value Assessment. The centers promote research, innovation, and the development of tools and partnerships that advance value-driven decision making and patient-centered care models. Each Center receives a three-year grant for $500,000.
The Research Consortium for Health Care Value Assessment
Hosted by: Altarum with its core partner, V-BID Health
Center Director: George Miller, PhD
The mission for Altarum and V-BID’s Value Consortium is to “promote the pursuit of value in health care delivery in the U.S. by identifying high- and low-value clinical services, tracking the use of such services, helping to ensure that consumer preferences are incorporated in health care decisions.” It is working with researchers to identify the strategies that lead to better value, such as health benefit designs that incentivize the use of high-value services and discourage the use of low-value services. Download our Info Sheet for Consortium details.
Latest News from the Research Consortium:
Patient Driven Values in Healthcare Evaluation (PAVE)
Hosted by: University of Maryland, Baltimore
Center Director: Susan dosReis, PhD
The University of Maryland, Baltimore’s Patient Driven Values in Healthcare Evaluation (PAVE) is devoted to “promoting the inclusion of diversity in patient voices regarding the elements of value most important to patients.” The vision of the new center, based at the University of Maryland School of Pharmacy, is for “patients and other stakeholders, such as value framework developers and users, to co-produce reliable and meaningful value assessments to support patient-centered health care decision-making.” Download our Info Sheet for PAVE details.
Patient-Centered Value Assessment: Hepatitis C (HCV) Treatment
PAVE researchers recently constructed a novel economic model to assess the value of Hepatitis C (HCV) treatments that incorporated two new patient-informed treatment outcomes — infected life-years and workdays missed. The results are illustrated in the infographic below — click it to see more details.
Latest News from PAVE:
Center for Enhanced Value Assessment (CEVA)
Hosted by: The Tufts Medical Center
Center Director – Peter J. Neumann, ScD
CEVA will be headquartered within Tufts’ Center for the Evaluation of Value and Risk in Health, founded in 2006 in Boston. CEVA’s mission will be to explore the quantitative incorporation of additional elements into traditional cost-effectiveness analysis (CEA). The new CEVA center will serve as a platform to focus on the proliferation of value-assessment frameworks in the United States — a relatively recent phenomenon in health care cost-effectiveness analysis. A key aspect of all value-assessment frameworks is a selection of value elements. An emphasis on cost-per-quality-adjusted life year (QALY) gained has long been endorsed by authoritative groups in the field of health economics. CEVA’s mission will be to explore the quantitative incorporation of additional elements into traditional measures, such as QALY, by developing and exploring the magnitude of enhanced cost-effectiveness elements; engaging patients and stakeholders to identify important novel and non-standard elements; and reporting findings back to stakeholders. Download our Info Sheet for CEVA details.
Latest News from CEVA:
Center for Pharmaceutical Value (pValue)
Hosted by: University of Colorado
Center Director: R. Brett McQueen, PhD
The mission of pValue is to apply and test novel methods for U.S. value assessments to improve coverage and reimbursement decision-making in health care. pValue is headquartered within the D2V initiative, a Transformational Research Funding project supported by the Dean’s Office of the University of Colorado School of Medicine. pValue will apply and test novel methods to improve the pharmaceutical coverage and reimbursement decision-making process, with the goal of improving transparency, consistency, and fairness of decisions. Specifically, pValue researchers will test multicriteria decision analysis (MCDA) as a decision tool. pValue pilot experiments will help determine where expanded decision tools should be used alongside existing approaches to maintain transparency and consistency while introducing more fairness in pharmaceutical coverage and reimbursement decision making in the U.S. Download our Info Sheet for pValue details.
Multi-Criteria Decision Analysis (MCDA)
pValue is breaking important new ground with Multi-Criteria Decision Analysis (MCDA), which is helping identify important criteria of value outside traditional understanding. To see a roadmap of the MCDA process, click image below.
Latest News from pVAlue: